Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
about
Implementation of a delirium assessment tool in the ICU can influence haloperidol use.Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadineMinimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia.Acute and chronic toxicity, cytochrome p450 enzyme inhibition, and HERG channel blockade studies with a polyherbal, ayurvedic formulation for inflammation.Apparent desensitization of the effects of sigma receptor ligand haloperidol in isolated rat and guinea pig hearts after chronic treatment.Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor?Delirium in intensive care unit patients.Prevention inherent in services for women with schizophrenia.The highest intentional ziprasidone overdose was not fatal.Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.Lack of relationship between plasma levels of escitalopram and QTc-interval length.Promethazine plus sumatriptan in the treatment of migraine: a randomized clinical trial.Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.Letter to the editor
P2860
Q30490490-4CC89C76-268D-4042-9D9C-9615405579A1Q34100661-2617173A-71B6-48C0-83D2-5C246A98E1F4Q35037346-16A52224-D44E-487A-BE84-18788B4B27AEQ36548372-DC66A4AD-DF52-40E1-A476-76BEA5D2E191Q37598547-4F86C797-BB86-4121-9088-5FAC08BD4E8BQ41999828-59034FCF-F82D-409A-8027-A2D79EA9B5B9Q43211133-899943AD-620F-49F9-B3AA-E4EEE28961DBQ44028648-9B7B048E-1912-47DD-8041-87EE09D3F844Q44549921-4FB63658-DD3F-4ECD-9DC1-D4FEE82B4949Q44740392-EBF4478B-47D6-4549-9134-D8A87251F93DQ46543473-257552B4-B985-45EA-A441-67810E974D14Q46698283-65BB9242-A1A0-40A1-8F4C-CB98E66AC6B2Q47819968-DCB09496-64DE-44E1-A2CD-8EEDC9C77CFCQ50758391-2B6E84E1-B2C6-4EEC-9F0C-E12C6675220AQ51331734-15D5B03B-42CC-4FB9-8929-CE23C362A08CQ57602718-F646A4EC-FF38-4CF1-8204-5B5F3A76A759
P2860
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
@ast
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
@en
type
label
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
@ast
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
@en
prefLabel
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
@ast
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
@en
P2093
P2860
P1476
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
@en
P2093
P2860
P304
P356
10.1111/J.1600-0447.2004.00469.X
P407
P577
2005-03-01T00:00:00Z